BioCentury | Oct 20, 2020
Management Tracks

J&J promotes Kumar; plus moves at Krystal, Design, Centogene, Lyndra, Mereo and Neoleukin

...release oral therapies, hired George Eldridge as CFO. Eldridge, who was most recently CFO at Proteon Therapeutics Inc....
BioCentury | Feb 8, 2020
Management Tracks

Gottlieb joins Illumina’s board; plus Kiniksa, Frequency, DBV, VectivBio and more

...development at Agios Pharmaceuticals Inc. (NASDAQ:AGIO). Najim was VP of manufacturing and process development at Proteon Therapeutics Inc....
BioCentury | May 9, 2019
Company News

Management tracks: Akebia, Sangamo, Bicycle

...other opportunities. She will be succeeded by Steven Burke, who was SVP and CMO of Proteon Therapeutics Inc....
BioCentury | Apr 6, 2019
Finance

Everybody up

...an oral, fixed dose combination of Molecular Solubility Enhanced Inclusion Complex (MoSEIC) meloxicam and rizatriptan. Proteon Therapeutics Inc....
...Corp. (NASDAQ:CELG), Summit, N.J. Inhibrx LLC, La Jolla, Calif. Invitae Corp. (NASDAQ:NVTA), San Francisco, Calif. Proteon Therapeutics Inc....
...Analytics 1315 Capital LLC Aptinyx Inc. Ascendis Pharma A/S Axsome Therapeutics Inc. BeiGene Ltd. Biogen Inc. bluebird bio Inc. Bristol-Myers Squibb Co. Celgene Corp. Invitae Corp. Proteon Therapeutics Inc. Roche SanBio...
BioCentury | Apr 5, 2019
Clinical News

Proteon's vonapanitase misses another Phase III

...hemodialysis (p=0.328) and secondary patency (p=0.932). The double-blind, North American trial enrolled about 600 patients. Proteon Therapeutics Inc....
...it will review the full data set from PATENCY-2 and evaluate strategic options. In 2016, Proteon...
...patency vs. placebo (p=0.254) in the Phase III PATENCY-1 trial in the same indication (see "Proteon...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Co. Ltd. (Tokyo:4506) Imeglimin (PXL008) Type II diabetes Phase III data (3 trials) 2Q19; 2H19 Proteon Therapeutics Inc....
BioCentury | May 17, 2017
Clinical News

Proteon's vonapanitase receives breakthrough therapy designation

...to correct a calculation error in the trial's statistical plan (see BioCentury, May 15 ). Proteon...
...submit the BLA in 2019. Proteon Therapeutics Inc. (NASDAQ:PRTO), Waltham, Mass. Product: Vonapanitase (formerly PRT-201) Business: Renal Alicia Parker vonapanitase Proteon Therapeutics Inc. Elastin...
BioCentury | May 12, 2017
Clinical News

Proteon ups Phase III PATENCY-2 enrollment

...enroll 600 CKD patients undergoing surgery for arteriovenous fistula (AVF) creation, up from 500 previously. Proteon...
...American trial is evaluating vonapanitase given immediately after radiocephalic AVF. Vonapanitase is recombinant human elastase. Proteon...
...the trial in 1Q19 and submit a BLA for vonapanitase in 2019. Earlier this year, Proteon...
BioCentury | Mar 17, 2017
Clinical News

Vonapanitase: Ph III PATENCY-2 amended

...from 300 and to establish secondary patency and fistula use for hemodialysis as co-primary endpoints. Proteon...
...met the secondary endpoint of improving secondary patency loss (see BioCentury, Dec. 16, 2016 ). Proteon Therapeutics Inc....
...III amended Milestone: Complete Phase III enrollment (4Q17); Phase III data (4Q18); submit BLA (2019) Julian Zhu vonapanitase Proteon Therapeutics Inc. Elastin...
BioCentury | Jan 6, 2017
Finance

Tiers of disappointment

...bococizumab to treat hypercholesterolemia due to higher rates of immunogenicity compared to other PCSK9 inhibitors Proteon Therapeutics Inc....
Items per page:
1 - 10 of 67
BioCentury | Oct 20, 2020
Management Tracks

J&J promotes Kumar; plus moves at Krystal, Design, Centogene, Lyndra, Mereo and Neoleukin

...release oral therapies, hired George Eldridge as CFO. Eldridge, who was most recently CFO at Proteon Therapeutics Inc....
BioCentury | Feb 8, 2020
Management Tracks

Gottlieb joins Illumina’s board; plus Kiniksa, Frequency, DBV, VectivBio and more

...development at Agios Pharmaceuticals Inc. (NASDAQ:AGIO). Najim was VP of manufacturing and process development at Proteon Therapeutics Inc....
BioCentury | May 9, 2019
Company News

Management tracks: Akebia, Sangamo, Bicycle

...other opportunities. She will be succeeded by Steven Burke, who was SVP and CMO of Proteon Therapeutics Inc....
BioCentury | Apr 6, 2019
Finance

Everybody up

...an oral, fixed dose combination of Molecular Solubility Enhanced Inclusion Complex (MoSEIC) meloxicam and rizatriptan. Proteon Therapeutics Inc....
...Corp. (NASDAQ:CELG), Summit, N.J. Inhibrx LLC, La Jolla, Calif. Invitae Corp. (NASDAQ:NVTA), San Francisco, Calif. Proteon Therapeutics Inc....
...Analytics 1315 Capital LLC Aptinyx Inc. Ascendis Pharma A/S Axsome Therapeutics Inc. BeiGene Ltd. Biogen Inc. bluebird bio Inc. Bristol-Myers Squibb Co. Celgene Corp. Invitae Corp. Proteon Therapeutics Inc. Roche SanBio...
BioCentury | Apr 5, 2019
Clinical News

Proteon's vonapanitase misses another Phase III

...hemodialysis (p=0.328) and secondary patency (p=0.932). The double-blind, North American trial enrolled about 600 patients. Proteon Therapeutics Inc....
...it will review the full data set from PATENCY-2 and evaluate strategic options. In 2016, Proteon...
...patency vs. placebo (p=0.254) in the Phase III PATENCY-1 trial in the same indication (see "Proteon...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Co. Ltd. (Tokyo:4506) Imeglimin (PXL008) Type II diabetes Phase III data (3 trials) 2Q19; 2H19 Proteon Therapeutics Inc....
BioCentury | May 17, 2017
Clinical News

Proteon's vonapanitase receives breakthrough therapy designation

...to correct a calculation error in the trial's statistical plan (see BioCentury, May 15 ). Proteon...
...submit the BLA in 2019. Proteon Therapeutics Inc. (NASDAQ:PRTO), Waltham, Mass. Product: Vonapanitase (formerly PRT-201) Business: Renal Alicia Parker vonapanitase Proteon Therapeutics Inc. Elastin...
BioCentury | May 12, 2017
Clinical News

Proteon ups Phase III PATENCY-2 enrollment

...enroll 600 CKD patients undergoing surgery for arteriovenous fistula (AVF) creation, up from 500 previously. Proteon...
...American trial is evaluating vonapanitase given immediately after radiocephalic AVF. Vonapanitase is recombinant human elastase. Proteon...
...the trial in 1Q19 and submit a BLA for vonapanitase in 2019. Earlier this year, Proteon...
BioCentury | Mar 17, 2017
Clinical News

Vonapanitase: Ph III PATENCY-2 amended

...from 300 and to establish secondary patency and fistula use for hemodialysis as co-primary endpoints. Proteon...
...met the secondary endpoint of improving secondary patency loss (see BioCentury, Dec. 16, 2016 ). Proteon Therapeutics Inc....
...III amended Milestone: Complete Phase III enrollment (4Q17); Phase III data (4Q18); submit BLA (2019) Julian Zhu vonapanitase Proteon Therapeutics Inc. Elastin...
BioCentury | Jan 6, 2017
Finance

Tiers of disappointment

...bococizumab to treat hypercholesterolemia due to higher rates of immunogenicity compared to other PCSK9 inhibitors Proteon Therapeutics Inc....
Items per page:
1 - 10 of 67